Alto Neuroscience Balance Sheet Health
Financial Health criteria checks 5/6
Alto Neuroscience has a total shareholder equity of $165.1M and total debt of $10.2M, which brings its debt-to-equity ratio to 6.2%. Its total assets and total liabilities are $191.6M and $26.6M respectively.
Key information
6.2%
Debt to equity ratio
US$10.16m
Debt
| Interest coverage ratio | n/a |
| Cash | US$181.70m |
| Equity | US$165.05m |
| Total liabilities | US$26.56m |
| Total assets | US$191.61m |
Financial Position Analysis
Short Term Liabilities: ANRO's short term assets ($183.5M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: ANRO's short term assets ($183.5M) exceed its long term liabilities ($12.5M).
Debt to Equity History and Analysis
Debt Level: ANRO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ANRO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANRO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 42.6% each year.